{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:54:45Z","timestamp":1784782485029,"version":"3.55.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity\/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era.<\/jats:p>","DOI":"10.1182\/bloodadvances.2018024844","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T12:16:29Z","timestamp":1541420189000},"page":"2922-2936","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia"],"prefix":"10.1182","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang Woo","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Institute for Health and Society, and"},{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Huan","family":"Hu","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Jain","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Assal","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6602-5505","authenticated-orcid":false,"given":"Jan","family":"Cerny","sequence":"additional","affiliation":[{"name":"UMass Memorial Medical Center, Worcester, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Copelan","sequence":"additional","affiliation":[{"name":"Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Daly","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre, Calgary, AB, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3255-8143","authenticated-orcid":false,"given":"Shahinaz M.","family":"Gadalla","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology & Genetics, National Cancer Institute Clinical Genetics Branch, National Institutes of Health, Rockville, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[{"name":"Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation, Division of Hematology and Oncology, University of Kansas Medical Center, Kansas City, KS;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty K.","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard Carl","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"Markey Cancer Center, University of Kentucky, Lexington, KY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Department of Medicine, Shands HealthCare & University of Florida, Gainesville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[{"name":"Division of Hematopoietic Stem Cell Transplantation, National Cancer Centers Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham S.","family":"Kanate","sequence":"additional","affiliation":[{"name":"Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Jean","family":"Khoury","sequence":"additional","affiliation":[{"name":"Emory University Hospital, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Seidman Cancer Center, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"Division of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-4265","authenticated-orcid":false,"given":"Sunita","family":"Nathan","sequence":"additional","affiliation":[{"name":"Rush University Medical Center, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Olsson","sequence":"additional","affiliation":[{"name":"Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;"},{"name":"Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaphol","family":"Pawarode","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Program, Division of Hematology\/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Ringden","sequence":"additional","affiliation":[{"name":"Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-0130","authenticated-orcid":false,"given":"Ayman","family":"Saad","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry C.","family":"Schouten","sequence":"additional","affiliation":[{"name":"Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Hematology & Oncology, National Cancer Research Center East, Chiba, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[{"name":"The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Stuart","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Woolfrey","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean A.","family":"Yared","sequence":"additional","affiliation":[{"name":"Blood & Marrow Transplantation Program, Division of Hematology\/Oncology, Department of Medicine, Greenebaum Cancer Center, University of Maryland, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[{"name":"Center of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt E.","family":"Kalaycio","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uday","family":"Popat","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Sobecks","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"2020021108392130500_B1","doi-asserted-by":"crossref","article-title":"Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase","author":"Ohanian","DOI":"10.1016\/j.clml.2013.08.008"},{"issue":"6","key":"2020021108392130500_B2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"10","key":"2020021108392130500_B3","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2020021108392130500_B4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","article-title":"Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia","volume":"137","author":"Giralt","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"2020021108392130500_B5","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood.V84.12.4368.bloodjournal84124368","article-title":"Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia","volume":"84","author":"Clift","year":"1994","journal-title":"Blood"},{"issue":"14","key":"2020021108392130500_B6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJM199804023381405","article-title":"Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia","volume":"338","author":"Hansen","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"2020021108392130500_B7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0002-9343(01)00629-5","article-title":"Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors","volume":"110","author":"Davies","year":"2001","journal-title":"Am J Med"},{"issue":"1","key":"2020021108392130500_B8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2020021108392130500_B9","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V80.5.1352.1352","article-title":"Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"issue":"7","key":"2020021108392130500_B10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.bbmt.2009.03.013","article-title":"Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia","volume":"15","author":"Copelan","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2020021108392130500_B11","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"issue":"17","key":"2020021108392130500_B12","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/blood-2012-02-409763","article-title":"Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era","volume":"119","author":"Warlick","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2020021108392130500_B13","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021108392130500_B14","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/sj.leu.2403967","article-title":"Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)","volume":"19","author":"Aoudjhane","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"2020021108392130500_B15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/sj.leu.2404010","article-title":"Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis","volume":"20","author":"Scott","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"2020021108392130500_B16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"issue":"9","key":"2020021108392130500_B17","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1182\/blood-2006-03-008706","article-title":"Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"108","author":"Martino","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2020021108392130500_B18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","article-title":"Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome","volume":"12","author":"Alyea","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"27","key":"2020021108392130500_B19","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringd\u00e9n","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2020021108392130500_B20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2011.69","article-title":"Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS","volume":"47","author":"Luger","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2020021108392130500_B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.bmt.1705879","article-title":"Comparable non-relapse mortality and survival after HLA-identical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission","volume":"41","author":"Martino","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2020021108392130500_B22","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"issue":"7","key":"2020021108392130500_B23","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"S2 Suppl 2","key":"2020021108392130500_B24","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"issue":"12","key":"2020021108392130500_B25","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020021108392130500_B26","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"8","key":"2020021108392130500_B27","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2020021108392130500_B28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmpb.2007.07.010","article-title":"A SAS macro for estimation of direct adjusted survival curves based on a stratified Cox regression model","volume":"88","author":"Zhang","year":"2007","journal-title":"Comput Methods Programs Biomed"},{"issue":"1","key":"2020021108392130500_B29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmpb.2010.07.005","article-title":"SAS macros for estimation of direct adjusted cumulative incidence curves under proportional subdistribution hazards models","volume":"101","author":"Zhang","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"issue":"8","key":"2020021108392130500_B30","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3324\/haematol.2012.076349","article-title":"Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study","volume":"98","author":"Gratwohl","year":"2013","journal-title":"Haematologica"},{"issue":"14","key":"2020021108392130500_B31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"11","key":"2020021108392130500_B32","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"2020021108392130500_B33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020021108392130500_B34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S1470-2045(12)70349-2","article-title":"Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial","volume":"13","author":"Bornh\u00e4user","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"2020021108392130500_B35","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2141.2005.05614.x","article-title":"Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation","volume":"130","author":"P\u00e9rez-Sim\u00f3n","year":"2005","journal-title":"Br J Haematol"},{"issue":"1","key":"2020021108392130500_B36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/bmt.2014.199","article-title":"Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML","volume":"50","author":"S\u00e9bert","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020021108392130500_B37","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission","volume":"116","author":"Marks","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2020021108392130500_B38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020021108392130500_B39","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/bmt.2011.10","article-title":"Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD","volume":"47","author":"Osumi","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2020021108392130500_B40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbmt.2017.10.021","article-title":"Anti-platelet-derived growth factor receptor alpha chain antibodies predict for response to nilotinib in steroid-refractory or -dependent chronic graft-versus-host disease","volume":"24","author":"Chen","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020021108392130500_B41","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2020021108392130500_B42","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria","year":"2007","journal-title":"Blood"},{"key":"2020021108392130500_B43","doi-asserted-by":"crossref","article-title":"Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk philadelphia chromosome-positive leukemia?","author":"DeFilipp","DOI":"10.1016\/j.clml.2016.04.017"},{"issue":"6","key":"2020021108392130500_B44","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/cncr.29141","article-title":"Phase 1\/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Shimoni","year":"2015","journal-title":"Cancer"},{"key":"2020021108392130500_B45","article-title":"Contemporary role of maintenance tyrosine kinase inhibitors following allogeneic hematopoietic cell transplantation for chronic myeloid leukemia: a CIBMTR analysis","author":"DeFilipp"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/21\/2922\/1629760\/advances024844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/21\/2922\/1629760\/advances024844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:13:38Z","timestamp":1581412418000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/21\/2922\/16189\/Myeloablative-vs-reducedintensity-conditioning"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,5]]},"references-count":45,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,11,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2018024844","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,5]]}}}